26 results match your criteria: "Australasian College of Cutaneous Oncology[Affiliation]"
J Clin Med
January 2025
Department of Surgery, Formerly of Royal Marsden Hospital, London SW3 6JJ, UK.
We note with interest the commentary by Pennington and Thompson (P&T) regarding our detailed update on the management of primary cutaneous melanoma in 2024 [...
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
September 2024
Formerly of Royal Marsden Hospital, London, UK.
J Eur Acad Dermatol Venereol
August 2024
Formerly of Royal Marsden Hospital, Chelsea, UK.
Background: The American Joint Committee on Cancer (AJCC) method of staging melanoma is dated and inaccurate. It ignores important prognostic melanoma features, especially the patient's age. BAUSSS is more accurate in determining survival risk for primary cutaneous melanoma patients who have no clinical or imaging evidence of nodal or distant metastases.
View Article and Find Full Text PDFJ Clin Med
March 2024
Department of Surgery, Formerly of Royal Marsden Hospital, London SW3 6JJ, UK.
: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve survival in high-risk melanoma patients. Despite well-documented guidelines, many patients do not receive optimal management, particularly when considering patient age.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
September 2024
Aristotle University of Thessaloniki, Thessaloniki, Greece.
J Eur Acad Dermatol Venereol
August 2024
Aristotle University of Thessaloniki, Thessaloniki, Greece.
J Eur Acad Dermatol Venereol
April 2024
Formerly of Royal Marsden Hospital, London, UK.
Background: Melanoma disease patterns vary with patient age.
Aim: To evaluate sentinel lymph node biopsy (SLNB) in managing melanoma at differing patient ages.
Methods: Online prediction tools were applied to compare SLNB positivity (SLNB) and survival risk at patient ages 20-80.
J Eur Acad Dermatol Venereol
October 2023
Formerly of Royal Marsden Hospital, Chelsea, London, UK.
Background: Breslow thickness, patient age and ulceration are the three most valuable clinical and pathological predictors of melanoma survival. A readily available reliable online tool that accurately considers these and other predictors could be valuable for clinicians managing melanoma patients.
Objective: To compare online melanoma survival prediction tools that request user input on clinical and pathological features.
J Eur Acad Dermatol Venereol
July 2023
Formerly of Royal Marsden Hospital, London, UK.
J Dtsch Dermatol Ges
October 2022
Dermatology Department, The Royal Melbourne Hospital, Melbourne, Australien.
J Dtsch Dermatol Ges
October 2022
Dermatology Department, The Royal Melbourne Hospital, Melbourne, Australia.
A fixed drug eruption (FDE) is a common cutaneous adverse drug reaction which occurs following administration of an offending drug. The aim of this review is to provide an update on the list of drugs causing FDE, with a focus on emerging drug culprits reported since the start of the century. Across published literature, triggers for FDE are widely varied.
View Article and Find Full Text PDFJ Am Acad Dermatol
November 2022
Department of Dermatology, University of California, Irvine, Irvine, California.
Am J Dermatopathol
April 2021
Australasian College of Cutaneous Oncology, Docklands, VIC, Australia.
Keratoacanthoma (KA) is a cutaneous tumor with a biphasic pattern of growth. A rapidly growing phase is usually followed by involution. KA occurs on sun-damaged skin.
View Article and Find Full Text PDFDermatol Surg
May 2021
Department of Dermatology, University of California, Irvine, California.
J Eur Acad Dermatol Venereol
October 2020
Australasian College of Cutaneous Oncology, Docklands, Australia.
J Eur Acad Dermatol Venereol
July 2020
Australasian College of Cutaneous Oncology, Docklands, Vic., Australia.
Merkel cell carcinoma (MCC) is an aggressive tumour with neuroendocrine differentiation. Clinically significant differences within the entity we know as MCC are apparent. This review aims to evaluate the evidence for differences in tumours within Merkel cell carcinoma and to stratify these.
View Article and Find Full Text PDFAust J Gen Pract
June 2019
PhD, MBBS, FRACGP, FRCP Edin, Professorial Fellow, Baker Heart@and Diabetes Institute, Melbourne, Vic.
Background: Several new medications have shown improved survival rates in high-risk patients with melanoma.
Objective: The aim of this article is to discuss the new medications and outline their roles, the expected benefit from each and the risk of adverse events. We explain the place of sentinel lymph node biopsy (SLNB) and ultrasonography with fine needle aspiration (US-FNA) in assessing and treating patients with melanoma.
Aust J Gen Pract
June 2019
PhD, MBBS, FRACGP, FRCP Edin, Professorial Fellow, Baker Heart@and Diabetes Institute, Melbourne, Vic.
Background: Maximising survival for patients with invasive melanoma hinges on early diagnosis of primary melanoma and appropriate management. Despite well-documented guidelines, many patients with melanoma have not been managed ideally.
Objective: The aim of this paper is to identify suboptimal aspects of melanoma management.
JAMA Dermatol
March 2019
Department of Dermatology, University of California, Irvine, Irvine, California.
JAMA Dermatol
July 2018
Department of Dermatology, University of California, Irvine.
Br J Dermatol
August 2017
Department of Dermatology, University of Tasmania, Hobart, Tasmania, Australia.
Br J Dermatol
December 2016
Baker IDI Heart and Diabetes Institute, Department of Research, Melbourne, Victoria, Australia.
Proc (Bayl Univ Med Cent)
April 2016
Texas A&M Health Science Center College of Medicine and DermOne Dermatology Clinics, Irving, Texas (Steinman); First Capitol Dermatology, St. Charles, Missouri (Clever); and Australasian College of Cutaneous Oncology, Victoria, Australia (Dixon).
Little is known about the practice characteristics of Mohs surgery performed by physicians who learned the procedure during their dermatology residency training or through postresidency courses and observational preceptorships. All published reports have investigated Mohs surgeons trained in postresidency fellowships. This report presents the results of a multicenter prospective cohort study evaluating 1834 consecutive Mohs surgery cases performed during the same 6-month period by 9 Mohs surgeons who learned the technique in residency or in postresidency courses and observational preceptorships.
View Article and Find Full Text PDFAust Fam Physician
July 2014
MBBS, PhD, FACRRM, MAOCD, Director of postgraduate education,Department of Cutaneous Oncology, Australasian College of Cutaneous Oncology, Belmont, VIC.
SLNB is confirmed as a prognostic test but does not influence melanoma-specific survival at 10 years. SLNB-negative patients still need regular review and can still die from their melanoma. SLNB-positive patients should be carefully counselled regarding the risks and very limited benefit (if any) of proceeding to CL.
View Article and Find Full Text PDF